Lab
Saint Francis Outreach Services LLC
Saint Francis Outreach Services LLC was paid $15.74M by Medicaid between Jan 2018 and Dec 2024, across 220 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 8.4% of everything it billed.
33Billing provider infoSAINT FRANCIS OUTREACH SERVICES LLC
TULSA, OK 74136
TULSA, OK 74136
33aNPI1740265347assigned 12/07/2005
33bProvider typeClinical Medical Laboratory
28Total paid$15.74M
24GClaims1,106,568
24DCodes billed220
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Oklahoma
Rank by total paid#4 of 46
Median peer was paid$248K
This provider vs. median63×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,792 | $1.36M | |
| 2019 | 116,135 | $1.39M | |
| 2020 | 128,173 | $2.10M | |
| 2021 | 173,360 | $2.95M | |
| 2022 | 210,823 | $3.12M | |
| 2023 | 204,446 | $2.69M | |
| 2024incomplete | 166,839 | $2.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.4% | 15,961 | 15,277 | $1.31M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.0% | 15,946 | 15,528 | $790K |
| 80050 | General health panel | 5.0% | 24,569 | 24,546 | $785K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.1% | 22,966 | 22,384 | $644K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.8% | 12,256 | 12,003 | $590K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.7% | 82,872 | 79,660 | $578K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.0% | 22,005 | 21,945 | $478K |
| 80053 | Comprehensive metabolic panel | 3.0% | 49,876 | 48,104 | $469K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.8% | 29,336 | 29,124 | $441K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.5% | 7,214 | 7,037 | $397K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.5% | 12,588 | 12,416 | $394K |
| 87581 | 2.5% | 12,591 | 12,418 | $393K |
208 more codes
| 87486 | 2.5% | 12,591 | $392K | |
| 80061 | Lipid panel | 2.3% | 30,347 | $362K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 8,658 | $272K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 8,662 | $272K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.7% | 31,111 | $269K |
| 86780 | 1.6% | 21,651 | $259K | |
| 87070 | 1.5% | 29,535 | $235K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.5% | 9,674 | $229K |
| 86359 | 1.4% | 6,732 | $225K | |
| 80074 | 1.4% | 5,183 | $220K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 7,770 | $205K |
| 86762 | 1.3% | 15,678 | $205K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 27,520 | $201K |
| 86803 | 1.2% | 15,245 | $194K | |
| 87340 | <1% | 16,373 | $153K | |
| 87077 | <1% | 17,613 | $153K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,448 | $151K |
| 86361 | <1% | 6,366 | $151K | |
| 86480 | <1% | 2,708 | $149K | |
| 81229 | <1% | 144 | $148K | |
| 86850 | <1% | 17,302 | $147K | |
| 84439 | <1% | 17,650 | $142K | |
| 83655 | <1% | 11,381 | $126K | |
| 85027 | <1% | 17,984 | $105K | |
| 87430 | <1% | 7,311 | $103K | |
| 81001 | <1% | 35,252 | $101K | |
| 84466 | <1% | 8,734 | $97K | |
| 81025 | <1% | 12,706 | $97K | |
| 82728 | <1% | 8,098 | $97K | |
| 80047 | <1% | 8,048 | $95K | |
| 84702 | <1% | 6,925 | $94K | |
| 87186 | <1% | 9,674 | $86K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,201 | $85K |
| 83880 | <1% | 2,257 | $77K | |
| 84403 | <1% | 3,278 | $74K | |
| 82784 | <1% | 6,625 | $73K | |
| 87088 | <1% | 9,467 | $73K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,720 | $70K |
| 87081 | <1% | 11,532 | $70K | |
| 82950 | <1% | 14,764 | $64K | |
| 86003 | <1% | 910 | $60K | |
| 83970 | <1% | 1,616 | $59K | |
| 82105 | <1% | 3,667 | $56K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,980 | $53K |
| 87807 | <1% | 4,448 | $52K | |
| 81003 | <1% | 25,023 | $52K | |
| 82570 | <1% | 10,898 | $51K | |
| 83540 | <1% | 8,909 | $50K | |
| 84481 | <1% | 3,185 | $48K | |
| 87210 | <1% | 8,956 | $46K | |
| 86140 | <1% | 9,906 | $45K | |
| 86900 | <1% | 16,419 | $45K | |
| 86901 | <1% | 16,185 | $44K | |
| 83001 | <1% | 2,665 | $43K | |
| 86038 | <1% | 4,001 | $43K | |
| 86787 | <1% | 2,917 | $43K | |
| 82951 | <1% | 3,583 | $42K | |
| 84270 | <1% | 2,068 | $39K | |
| 86336 | <1% | 2,697 | $39K | |
| 82670 | <1% | 1,620 | $39K | |
| 87808 | <1% | 2,884 | $38K | |
| 84146 | <1% | 2,084 | $36K | |
| 83735 | <1% | 5,997 | $35K | |
| 82785 | <1% | 2,450 | $35K | |
| 82247 | <1% | 6,976 | $32K | |
| 80076 | <1% | 4,104 | $30K | |
| 82043 | <1% | 5,614 | $29K | |
| 82248 | <1% | 6,141 | $28K | |
| 83525 | <1% | 2,547 | $26K | |
| 82607 | <1% | 1,972 | $26K | |
| 85652 | <1% | 10,968 | $26K | |
| 86376 | <1% | 2,000 | $26K | |
| 87631 | <1% | 206 | $25K | |
| 83002 | <1% | 1,507 | $24K | |
| 85007 | <1% | 7,012 | $23K | |
| 85610 | <1% | 6,183 | $23K | |
| 80069 | <1% | 2,981 | $23K | |
| 86364 | <1% | 2,207 | $23K | |
| 86403 | <1% | 2,254 | $23K | |
| 83993 | <1% | 1,309 | $23K | |
| 83520 | <1% | 1,386 | $22K | |
| 84703 | <1% | 3,202 | $21K | |
| 87205 | <1% | 5,133 | $20K | |
| 84156 | <1% | 5,835 | $19K | |
| 87075 | <1% | 2,206 | $19K | |
| 87116 | <1% | 1,840 | $18K | |
| 83690 | <1% | 2,988 | $18K | |
| 84144 | <1% | 988 | $18K | |
| 84550 | <1% | 4,051 | $16K | |
| 84153 | <1% | 977 | $16K | |
| 84480 | <1% | 1,247 | $15K | |
| 86160 | <1% | 857 | $15K | |
| 86800 | <1% | 1,067 | $15K | |
| 82977 | <1% | 2,287 | $15K | |
| 86258 | <1% | 1,365 | $15K | |
| 86696 | <1% | 837 | $14K | |
| 86706 | <1% | 1,464 | $14K | |
| 86592 | <1% | 3,542 | $14K | |
| 83615 | <1% | 2,464 | $13K | |
| 83013 | <1% | 218 | $13K | |
| 82103 | <1% | 1,025 | $12K | |
| 82952 | <1% | 3,230 | $12K | |
| 84100 | <1% | 2,681 | $11K | |
| 86431 | <1% | 2,133 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 615 | $10K |
| 82550 | <1% | 1,791 | $10K | |
| 87206 | <1% | 1,949 | $10K | |
| 86317 | <1% | 325 | $9K | |
| 82746 | <1% | 638 | $8K | |
| 86665 | <1% | 477 | $8K | |
| 85730 | <1% | 1,393 | $8K | |
| 84484 | <1% | 688 | $8K | |
| 82533 | <1% | 524 | $7K | |
| 87902 | <1% | 31 | $7K | |
| 86200 | <1% | 558 | $6K | |
| 86757 | <1% | 258 | $6K | |
| 85045 | <1% | 1,696 | $6K | |
| 86235 | <1% | 100 | $6K | |
| 84305 | <1% | 311 | $6K | |
| 87338 | <1% | 451 | $6K | |
| 86695 | <1% | 479 | $6K | |
| 80177 | <1% | 457 | $5K | |
| 83010 | <1% | 469 | $5K | |
| 83516 | <1% | 301 | $5K | |
| 82627 | <1% | 248 | $5K | |
| 87046 | <1% | 278 | $4K | |
| 80197 | <1% | 360 | $4K | |
| 86147 | <1% | 166 | $4K | |
| 86705 | <1% | 391 | $4K | |
| 87328 | <1% | 325 | $4K | |
| 84165 | <1% | 418 | $4K | |
| 87209 | <1% | 235 | $4K | |
| 87329 | <1% | 317 | $3K | |
| 85018 | <1% | 1,530 | $3K | |
| 81596 | <1% | 50 | $3K | |
| 86677 | <1% | 187 | $3K | |
| 86225 | <1% | 244 | $3K | |
| 85379 | <1% | 305 | $3K | |
| 86666 | <1% | 221 | $3K | |
| 84445 | <1% | 61 | $3K | |
| 87427 | <1% | 238 | $3K | |
| 86618 | <1% | 165 | $3K | |
| 86778 | <1% | 184 | $2K | |
| 87045 | <1% | 269 | $2K | |
| 86704 | <1% | 217 | $2K | |
| 85014 | <1% | 968 | $2K | |
| 86777 | <1% | 169 | $2K | |
| 81050 | <1% | 668 | $2K | |
| 82677 | <1% | 87 | $2K | |
| 82525 | <1% | 189 | $2K | |
| 82787 | <1% | 113 | $2K | |
| 83021 | <1% | 123 | $2K | |
| 84681 | <1% | 105 | $2K | |
| 87177 | <1% | 233 | $2K | |
| 85660 | <1% | 329 | $2K | |
| 84630 | <1% | 161 | $2K | |
| 85613 | <1% | 171 | $2K | |
| 82150 | <1% | 275 | $2K | |
| 82671 | <1% | 55 | $2K | |
| 86694 | <1% | 124 | $2K | |
| 80164 | <1% | 126 | $2K | |
| 83014 | <1% | 206 | $1K | |
| 84255 | <1% | 66 | $1K | |
| 86708 | <1% | 124 | $1K | |
| 82465 | <1% | 306 | $1K | |
| 83498 | <1% | 50 | $1K | |
| 86664 | <1% | 89 | $1K | |
| 87536 | <1% | 15 | $1K | |
| 82947 | <1% | 308 | $1K | |
| 86769 | <1% | 26 | $1K | |
| 86334 | <1% | 56 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| 87529 | <1% | 33 | $1K | |
| 85670 | <1% | 202 | $1K | |
| 86663 | <1% | 88 | $968.61 | |
| 87076 | <1% | 109 | $917.65 | |
| 82024 | <1% | 26 | $893.10 | |
| 82274 | <1% | 56 | $794.72 | |
| 86146 | <1% | 24 | $792.40 | |
| 80305 | <1% | 68 | $740.30 | |
| 86036 | <1% | 46 | $707.52 | |
| 84590 | <1% | 62 | $637.33 | |
| 84446 | <1% | 49 | $592.67 | |
| 83521 | <1% | 38 | $587.50 | |
| 83789 | <1% | 29 | $575.70 | |
| 86648 | <1% | 44 | $574.42 | |
| 86774 | <1% | 43 | $556.89 | |
| 86360 | <1% | 13 | $543.27 | |
| 86015 | <1% | 50 | $513.00 | |
| 82088 | <1% | 12 | $411.08 | |
| 86355 | <1% | 13 | $402.72 | |
| 86645 | <1% | 25 | $374.75 | |
| 86357 | <1% | 12 | $369.16 | |
| 86644 | <1% | 26 | $345.60 | |
| 86341 | <1% | 15 | $314.55 | |
| 86671 | <1% | 13 | $261.60 | |
| 82656 | <1% | 24 | $246.24 | |
| 83721 | <1% | 25 | $224.16 | |
| 82140 | <1% | 15 | $194.40 | |
| 86904 | <1% | 14 | $188.16 | |
| 82378 | <1% | 12 | $185.46 | |
| 84155 | <1% | 59 | $184.74 | |
| 87040 | <1% | 13 | $165.24 | |
| 86256 | <1% | 12 | $128.64 | |
| 87102 | <1% | 17 | $127.16 | |
| 82390 | <1% | 12 | $114.60 | |
| 87184 | <1% | 12 | $73.15 | |
| 82040 | <1% | 13 | $57.20 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, BARRY (SYSTEM DIRECTOR, REV CYCLE SUPPORT)
| Provider | Location | Paid |
|---|---|---|
| Saint Francis Hospital Muskogee INC | Muskogee, OK | $16.79M |
| Saint Francis Hospital South LLC | Tulsa, OK | $11.12M |
| Saint Francis Hospital Vinita, INC | Vinita, OK | $6.44M |
| Laureate Psychiatric Clinic and Hospital INC | Tulsa, OK | $729K |
| Saint Francis Hospital South LLC | Tulsa, OK | $51K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.